USTR requested to reconsider Original Medicine Cost Collection Act

The U.S. has expressed a sensitive response to the amendment to the National Health Insurance Act for the Patent-Linkage System’s Medicine Cost Collection on Original Companies, which has been docked in the National Assembly. The rumor is that the states requested the Korean government to reconsider the amendment as ‘innocent patentees’ may receive damages.

According to the industry concerned ...